CD274 and non-small cell lung carcinoma: Results from the study indicated that pembrolizumab combined with NK cell therapy improved OS and PFS in patients with previously treated advanced PD-L1 NSCLC without causing any serious adverse effects compared to pembrolizumab alone, showing significant potential for NK cell immunotherapy (Table 1) [162,190].